Combining Erlotinib with Cytotoxic Chemotherapy May Overcome Resistance Caused by T790M Mutation of EGFR Gene in Non-Small Cell Lung Carcinoma

Journal of Lung Cancer 2009³â 8±Ç 2È£ p.92 ~ p.98

¿ÀÀÎÀç(Oh In-Jae) - Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ È­¼øÀü³²´ëÇб³º´¿ø È£Èí±â°ú Æó¾Ï,½Äµµ¾Ï ¼¾ÅÍ
±è±Ô½Ä(Kim Kyu-Sik) - Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ È­¼øÀü³²´ëÇб³º´¿ø È£Èí±â°ú Æó¾Ï,½Äµµ¾Ï ¼¾ÅÍ
Á¤ÁÖ¿¬(Jeong Ju-Yeon) - Àü³²´ëÇб³ Center for Biomedical Human Resources The Brain Korea 21 Project
Á¶ÇöÁÖ(Cho Hyun-Ju) - Àü³²´ëÇб³ Center for Biomedical Human Resources The Brain Korea 21 Project
±è¿µÃ¶(Kim Young-Chul) - Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ È­¼øÀü³²´ëÇб³º´¿ø È£Èí±â°ú Æó¾Ï,½Äµµ¾Ï ¼¾ÅÍ

Abstract

Å°¿öµå

Erlotinib, Drug therapy, Non-small-cell lung carcinoma, T790M
KMID : 0982820090080020092
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
The sequential treatment of cytotoxic chemotherapy followed by EGFR-TKI may overcome EGFR-TKI resistance.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå